Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clopidogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopidogrel SCHEMBL754557 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL30388817 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL19148648 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL14009483 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031641 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL29793709 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL5567933 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL4769 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1130036 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1402209 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798022-A | Method for splitting clopidogrel and camphorsulfonic acid | 惠州信立泰药业有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-11904051-B2 | Shear stress sensitive liposomes | UNIVERSITÄT BASEL (CH) | 2024-02-20 | — | — | US | claimed |
| US-7714133-B2 | Method for manufacturing crystalline form I of clopidogrel hydrogen sulphate | ZENTIVA, K.S. (CZ) | 2010-05-11 | — | — | US | claimed |
| EP-2084164-A2 | IMPROVED PROCESS FOR PREPARING CLOPIDOGREL | Teva Pharmaceutical Industries Ltd. (IL) | 2009-08-05 | — | — | EP | claimed |
| US-20080287679-A1 | Process for preparing clopidogrel | TEVA PHARMACEUTICALS USA, INC. | 2008-11-20 | — | — | US | claimed |
| WO-2008130642-A2 | IMPROVED PROCESS FOR PREPARING CLOPIDOGREL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-30 | — | — | WO | claimed |
| EP-1554284-B1 | METHOD FOR MANUFACTURING CRYSTALLINE FORM I OF CLOPIDOGREL HYDROGEN SULPHATE | ZENTIVA AS (CZ) | 2008-10-22 | — | — | EP | claimed |
| US-20060041136-A1 | Method for manufacturing crystalline form I of clopidogrel hydrogen sulphate | ZENTIVA, A.S. (CZ) | 2006-02-23 | — | — | US | claimed |
| EP-1606231-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | Nadkarni, Sunil Sadanand (IN) | 2005-12-21 | — | — | EP | claimed |
| EP-1554284-A1 | METHOD FOR MANUFACTURING CRYSTALLINE FORM I OF CLOPIDOGREL HYDROGEN SULPHATE | ZENTIVA, A.S. (CZ) | 2005-07-20 | — | — | EP | claimed |
| US-20050049415-A1 | Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives | MERCK GENERICS (UK) LIMITED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2004108665-A2 | A PROCESS FOR PREPARATION OF CLOPIDOGREL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-12-16 | — | — | WO | claimed |
| WO-2004074215-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | NADKARNI SUNIL SADANAND (IN) | 2004-09-02 | — | — | WO | claimed |
| WO-2004020443-A1 | METHOD FOR MANUFACTURING CRYSTALLINE FORM I OF CLOPIDOGREL HYDROGEN SULPHATE | ZENTIVA, A.S. (CZ) | 2004-03-11 | — | — | WO | claimed |
| EP-0465358-B1 | 2-Thienylglycidic acid derivative, process for its preparation and its use as synthetic intermediate | SANOFI SA (FR) | 1996-02-07 | — | — | EP | claimed |
| US-5132435-A | From 2-theinylcarboxaldehyde and an isopropyl haloacetate; for making 2-thienlacetaldoxime and thieno 9(3,2-c)pyridine derivatives | SANOFI (FR) | 1992-07-21 | — | — | US | claimed |
| US-4529596-A | Anticoagulant; clopidogrel (Methyl Alpha -(4,5,6,7-tetrahydro-thieno(3,2-c)-5-pyridyl)-o-chlorophenyl-acetate) | SANOFI, S.A. (FR) | 1985-07-16 | — | — | US | claimed |
| US-20260055190-A1 | ANTIBODIES FOR PLATELET FCyRIIA AND RELATED METHODS OF USE | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-5132435-A | From 2-theinylcarboxaldehyde and an isopropyl haloacetate; for making 2-thienlacetaldoxime and thieno 9(3,2-c)pyridine derivatives | SANOFI (FR) | 1992-07-21 | — | — | US | disclosed |
| US-4529596-A | Anticoagulant; clopidogrel (Methyl Alpha -(4,5,6,7-tetrahydro-thieno(3,2-c)-5-pyridyl)-o-chlorophenyl-acetate) | SANOFI, S.A. (FR) | 1985-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11904051-B2 | Shear stress sensitive liposomes | PHOSPHO1, SMPD4, LIPA | P2RY12 524/4885ABCB11 781/4885OPRM1 3698/4885 |
| US-20080287679-A1 | Process for preparing clopidogrel | P2RY6, P2RY12, P2RY11 | P2RY12 2/4885ABCB11 290/4885OPRM1 3274/4885 |
| US-20260055190-A1 | ANTIBODIES FOR PLATELET FCyRIIA AND RELATED METHODS OF USE | FCGR3B, FCGR2A, FCGR1A | P2RY12 18/4885ABCB11 4738/4885OPRM1 3891/4885 |
| US-20060041136-A1 | Method for manufacturing crystalline form I of clopidogrel hydrogen sulphate | ADH1C, ADH1A, F12 | P2RY12 112/4885ABCB11 1177/4885OPRM1 1223/4885 |
| US-20050049415-A1 | Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives | NR1H3, NR1H2, NR1H4 | P2RY12 1719/4885ABCB11 300/4885OPRM1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.